Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lir Life SciencesBBCMF +300.00%14 Price-to-Tangible-Book is 11.76 as of Sep. 09, 2026. GuruFocus rates BBCMF with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Lir Life Sciences ranks worse than 89.17% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Lir Life Sciences Price-to-Tangible-Book Related Terms
Lir Life Sciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBCMF vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Lir Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Lir Life Sciences (BBCMF) has a Price-to-Tangible-Book of 11.76 as of Sep. 09, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #1005 out of 1127 companies in the Biotechnology industry, placing it in the top 89.2%.
Is Lir Life Sciences' Price-to-Tangible-Book too high?
Lir Life Sciences' current Price-to-Tangible-Book is 11.76. The Biotechnology industry median Price-to-Tangible-Book is 3.37. Lir Life Sciences' value of 11.76 is 249% above this industry median. Based on the distribution chart, Lir Life Sciences ranks #1005 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #1005 out of 1127 companies for Price-to-Tangible-Book. This places Lir Life Sciences in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.37. Lir Life Sciences' value of 11.76 is 249% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.37, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Price-to-Tangible-Book of 11.76 is 249% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Price-to-Tangible-Book is 11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Price-to-Tangible-Book of 11.76. The current Price-to-Tangible-Book is 11.76 and 249% above the Biotechnology industry median of 3.37. Lir Life Sciences' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Price-to-Tangible-Book is 11.76 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
14GF Score
Get the complete analysis for BBCMF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 
